Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 2 121-126, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Circulating vitamin D metabolites in relation to subsequent development of prostate cancer

PH Gann, J Ma, CH Hennekens, BW Hollis, JG Haddad and MJ Stampfer
Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

An emerging hypothesis suggests that vitamin D metabolites suppress the development of prostate cancer. In a recent epidemiological study, elevated levels of 1,25-dihydroxyvitamin D (1,25-D) in blood were associated with a greatly reduced risk, particularly in older men. We conducted a nested case-control study to evaluate the relationship between plasma levels of the two major vitamin D metabolites, 1,25-D and 25-hydroxyvitamin D (25-D), and subsequent diagnosis of prostate cancer. We also measured vitamin D-binding protein to investigate the influence of free metabolite levels on risk. Plasma samples from 14,916 participants in the Physicians' Health Study were collected and frozen in 1982-1983. This analysis included 232 cases diagnosed up to 1992 and 414 age-matched control participants. Vitamin D metabolite and vitamin D-binding protein assays were conducted without knowledge of case-control status. Median levels of 25-D, 1,25-D, and vitamin D-binding protein were indistinguishable between cases and controls. Analysis of risk for increasing quartiles of total or free metabolites did not reveal a pattern of decreasing risk. For 1,25-D, men in the highest quartile had an odds ratio of 0.88 (95% confidence interval = 0.53-1.45) compared to those in the lowest quartile. Significant reductions in risk were not seen in analyses restricted to older men, to cases occurring > 3 years from blood collection, or to cases presenting as aggressive prostate cancer. Nonsignificant inverse associations for 1,25-D appeared for some groups according to 25-D level, particularly when the cutoff for defining low 25-D was reduced. These results do not support the hypothesis that high circulating levels of vitamin D metabolites reduce prostate cancer risk, although small to moderate effects cannot be excluded.

This article has been cited by other articles:

				J. Ahn, U. Peters, D. Albanes, M. P. Purdue, C. C. Abnet, N. Chatterjee, R. L. Horst, B. W. Hollis, W.-Y. Huang, J. M. Shikany, et al. Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case-Control Study J Natl Cancer Inst, June 4, 2008; 100(11): 796 - 804. [Abstract] [Full Text] [PDF]

				J. M. Faupel-Badger, L. Diaw, D. Albanes, J. Virtamo, K. Woodson, and J. A. Tangrea Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2784 - 2786. [Full Text] [PDF]

				Y. Park, P. N. Mitrou, V. Kipnis, A. Hollenbeck, A. Schatzkin, and M. F. Leitzmann Calcium, Dairy Foods, and Risk of Incident and Fatal Prostate Cancer: The NIH-AARP Diet and Health Study Am. J. Epidemiol., December 1, 2007; 166(11): 1270 - 1279. [Abstract] [Full Text] [PDF]

				C. N. Holick, J. L. Stanford, E. M. Kwon, E. A. Ostrander, S. Nejentsev, and U. Peters Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1990 - 1999. [Abstract] [Full Text] [PDF]

				P. Tuohimaa, L. Tenkanen, H. Syvala, S. Lumme, T. Hakulinen, J. Dillner, and M. Hakama Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 302 - 307. [Abstract] [Full Text] [PDF]

				E. Giovannucci, Y. Liu, E. B. Rimm, B. W. Hollis, C. S. Fuchs, M. J. Stampfer, and W. C. Willett Prospective study of predictors of vitamin d status and cancer incidence and mortality in men. J Natl Cancer Inst, April 5, 2006; 98(7): 451 - 459. [Abstract] [Full Text] [PDF]

				E. Giovannucci, Y. Liu, M. J. Stampfer, and W. C. Willett A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 203 - 210. [Abstract] [Full Text] [PDF]

				C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr, and M. F. Holick The Role of Vitamin D in Cancer Prevention Am J Public Health, February 1, 2006; 96(2): 252 - 261. [Abstract] [Full Text] [PDF]

				E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF]

				J. A. Baron, M. Beach, K. Wallace, M. V. Grau, R. S. Sandler, J. S. Mandel, D. Heber, and E. R. Greenberg Risk of Prostate Cancer in a Randomized Clinical Trial of Calcium Supplementation Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 586 - 589. [Abstract] [Full Text] [PDF]

				A. Jemal, E. Ward, X. Wu, H. J. Martin, C. C. McLaughlin, and M. J. Thun Geographic Patterns of Prostate Cancer Mortality and Variations in Access to Medical Care in the United States Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 590 - 595. [Abstract] [Full Text] [PDF]

				L. V. Stewart and N. L. Weigel Vitamin D and Prostate Cancer Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284. [Abstract] [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF]

				C. Rodriguez, M. L. McCullough, A. M. Mondul, E. J. Jacobs, D. Fakhrabadi-Shokoohi, E. L. Giovannucci, M. J. Thun, and E. E. Calle Calcium, Dairy Products, and Risk of Prostate Cancer in a Prospective Cohort of United States Men Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 597 - 603. [Abstract] [Full Text] [PDF]

				P. A. Newcomb, H. Kim, A. Trentham-Dietz, F. Farin, D. Hunter, and K. M. Egan Vitamin D Receptor Polymorphism and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1503 - 1504. [Full Text] [PDF]

				R. Vieth Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, August 1, 2002; 76(2): 490 - 491. [Full Text]

				D M Freedman, M Dosemeci, and K McGlynn Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study Occup. Environ. Med., April 1, 2002; 59(4): 257 - 262. [Abstract] [Full Text] [PDF]

				J. M Chan, M. J Stampfer, J. Ma, P. H Gann, J M. Gaziano, and E. L Giovannucci Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, October 1, 2001; 74(4): 549 - 554. [Abstract] [Full Text] [PDF]

				E. A. Platz, E. B. Rimm, W. C. Willett, P. W. Kantoff, and E. Giovannucci Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health Professionals J Natl Cancer Inst, December 20, 2000; 92(24): 2009 - 2017. [Abstract] [Full Text] [PDF]

				R. Vieth Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety Am. J. Clinical Nutrition, May 1, 1999; 69(5): 842 - 856. [Abstract] [Full Text] [PDF]

				B. L. Lokeshwar, G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhuang, N. L. Block, and L. Binderup Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089 Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 241 - 248. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]